Page 577 - Cardiac Nursing

53
53
e 5
Apt
9/0
9/2
ara
p53
P
P
g
M
009
8:2
9 A
0
K34
L L LWB
7-5
23_
0-c
K34
qxd
54.
LWB K34 0-c 23_ p53 7-5 54. qxd 0 9/0 9/2 009 0 0 8:2 9 A M P a a g e 5 53 Apt ara
54.
LWBK340-c23_23_p537-554.qxd 09/09/2009 08:29 AM Page 553 Aptara
CHAPTER 23 / Interventional Cardiology Techniques: Percutaneous Coronary Intervention 553
45. Cuisset, T., Frere, C., Quilici, J., et al. (2006). Benefit of a 600-mg loading 64. Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., et al. (2006). Late
dose of clopidogrel on platelet reactivity and clinical outcomes in patients clinical events after clopidogrel discontinuation may limit the benefit of
with non-ST-segment elevation acute coronary syndrome undergoing coro- drug-eluting stents: An observational study of drug-eluting versus bare-
nary stenting. Journal of the American College of Cardiology, 48(7), metal stents. Journal of the American College of Cardiology, 48(12),
1339–1345. 2584–2591.
46. Kastrati, A., Mehilli, J., Neumann, F. J., et al. (2006). Abciximab in pa- 65. Buonamici, P., Marcucci, R., Migliorini, A., et al. (2007). Impact of
tients with acute coronary syndromes undergoing percutaneous coronary platelet reactivity after clopidogrel administration on drug-eluting stent
intervention after clopidogrel pretreatment: The ISAR-REACT 2 ran- thrombosis. Journal of the American College of Cardiology, 49(24),
domized trial. JAMA, 295(13), 1531–1538. 2312–2317.
47. Antman, E. M., Morrow, D. A., McCabe, C. H., et al. (2006). Enoxaparin 66. Lev, E. I., Patel, R. T., Maresh, K. J., et al. (2006). Aspirin and clopidogrel
versus unfractionated heparin with fibrinolysis for ST-elevation myocardial drug response in patients undergoing percutaneous coronary intervention:
infarction. New England Journal of Medicine, 354(14), 1477–1488. The role of dual drug resistance. Journal of the American College of Cardiology,
7
48. Collet, J. P., Montalescot, G., Lison, L., et al. (2001). Percutaneous coro- 47(1), 27–33.
7
nary intervention after subcutaneous enoxaparin pretreatment in patients 67. Bavry, A. A., Kumbhani, D. J., Helton, T. J., et al. (2006). Late thrombo-
with unstable angina pectoris. Circulation, 103(5), 658–663. sis of drug-eluting stents: A meta-analysis of randomized clinical trials.
49. EPIC Investigators. (1994). Use of a monoclonal antibody directed against American Journal of Medicine, 119(12), 1056–1061.
the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio- 68. Brilakis, E. S., Banerjee, S., & Berger, P. B. (2007). Perioperative manage-
plasty. The EPIC Investigation. New England Journal of Medicine, 330(14), ment of patients with coronary stents. Journal of the American College of
956–961. Cardiology, 49(22), 2145–2150.
50. EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa receptor 69. Deelstra, M. H. (1993). Coronary rotational ablation: An overview with
blockade and low-dose heparin during percutaneous coronary revascular- related nursing interventions. American Journal of Critical Care, 2(1),
ization. The EPILOG Investigators. New England Journal of Medicine, 16–25; quiz 26–17.
6
336(24), 1689–1696. 70. Ellis, S. G., Savage, M., Fischman, D., et al. (1992). Restenosis after place-
6
51. EPISTENT Investigators. (1998). Randomised placebo-controlled and ment of Palmaz-Schatz stents in native coronary arteries. Initial results of
6
6
balloon-angioplasty-controlled trial to assess safety of coronary stenting a multicenter experience. Circulation, 86(6), 1836–1844.
with use of platelet glycoprotein-IIb/IIIa blockade. Lancet, 352(9122), 71. Haude, M., Baumgart, D., & Ge, J. (2000). The restenotic lesion. In S.
87–92. G. Ellis & D. R. Holmes (Eds.), Strategic approaches in coronary interven-
52. PRISM-PLUS Investigators. (1998). Inhibition of the platelet glycopro- tion (2nd ed., pp. 296–324). Philadelphia: Lippincott Williams &
tein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave Wilkins.
myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome 72. Teirstein, P. S., & Kuntz, R. E. (2001). New frontiers in interventional car-
Management in Patients Limited by Unstable Signs and Symptoms diology: Intravascular radiation to prevent restenosis. Circulation, 104(21),
(PRISM-PLUS) Study Investigators. New England Journal of Medicine, 2620–2626.
338(21), 1488–1497. 73. Colombo, A., Hall, P., Nakamura, S., et al. (1995). Intracoronary stenting
53. Moreno, R., Fernandez, C., Hernandez, R., et al. (2005). Drug-eluting without anticoagulation accomplished with intravascular ultrasound guid-
stent thrombosis: Results from a pooled analysis including 10 randomized ance. Circulation, 91(6), 1676–1688.
studies. Journal of the American College of Cardiology, 45(6), 954–959. 74. Mukherjee, D., & Moliterno, D. J. (2006). Brachytherapy for in-stent
54. Cavallini, C., Savonitto, S., Violini, R., et al. (2005). Impact of the eleva- restenosis: A distant second choice to drug-eluting stent placement.
tion of biochemical markers of myocardial damage on long-term mortal- JAMA, 295(11), 1307–1309.
ity after percutaneous coronary intervention: Results of the CK-MB and 75. Holmes, D. R., Jr., Teirstein, P., Satler, L., et al. (2006). Sirolimus-eluting
6
6
PCI study. European Heart Journal, 26(15), 1494–1498. stents vs vascular brachytherapy for in-stent restenosis within bare-metal
55. Ramana, R. K., Arab, D., Joyal, D., et al. (2005). Coronary artery perfo- stents: The SISR randomized trial. JAMA, 295(11), 1264–1273.
ration during percutaneous coronary intervention: Incidence and out- 76. Stone, G. W., Ellis, S. G., O’Shaughnessy, C. D., et al. (2006). Paclitaxel-
comes in the new interventional era. Journal of Invasive Cardiology, 17(11), eluting stents vs vascular brachytherapy for in-stent restenosis within bare-
7
7
603–605. metal stents: The TAXUS V ISR randomized trial. JAMA, 295(11),
56. Klein, L. W. (2006). Coronary artery perforation during interventional 1253–1263.
procedures. Catheterization and Cardiovascular Interventions, 68(5), 77. Hasdai, D., Holmes, D. R., & Lerman, A. (2000). Evaluating stenosis
713–717. severity: Quantitative angiography, coronary flow reserve, and intravascu-
57. Baim, D. S., & Simon, D. I. (2006). Complications and optimal use of lar ultrasound. In S. G. Ellis & D. R. Holmes (Eds.), Strategic approaches
adjunctive pharmacology. In D. S. Baim (Ed.), Grossman’s cardiac catheter- in coronary intervention (2nd ed., pp. 175–184). Philadelphia: Lippincott
ization, angiography, and intervention (7th ed., pp. 36–76). Philadelphia: Williams & Wilkins.
Lippincott Williams & Wilkins. 78. King, T. D., Thompson, S. L., Steiner, C., et al. (1976). Secundum atrial
58. Laskey, W., Boyle, J., & Johnson, L. W. (1993). Multivariable model for septal defect. Nonoperative closure during cardiac catheterization. JAMA,
prediction of risk of significant complication during diagnostic cardiac 235(23), 2506–2509.
catheterization. The Registry Committee of the Society for Cardiac An- 79. Amin, Z., Hijazi, Z. M., Bass, J. L., et al. (2004). Erosion of Amplatzer
giography & Interventions. Catheterization and Cardiovascular Diagnosis, septal occluder device after closure of secundum atrial septal defects:
30(3), 185–190. Review of registry of complications and recommendations to minimize
59. Bogart, D. B., Bogart, M. A., Miller, J. T., et al. (1995). Femoral artery future risk. Catheterization and Cardiovascular Interventions, 63(4),
catheterization complications: A study of 503 consecutive patients. 496–502.
Catheterization and Cardiovascular Diagnosis, 34(1), 8–13. 80. Jones, T. K., Latson, L. A., Zahn, E., et al. (2007). Results of the U.S. mul-
60. Kinnaird, T. D., Stabile, E., Mintz, G. S., et al. (2003). Incidence, predic- ticenter pivotal study of the HELEX septal occluder for percutaneous clo-
tors, and prognostic implications of bleeding and blood transfusion follow- sure of secundum atrial septal defects. Journal of the American College of
ing percutaneous coronary interventions. American Journal of Cardiology, Cardiology, 49(22), 2215–2221.
92(8), 930–935. 81. Di Tullio, M. R., Sacco, R. L., Sciacca, R. R., et al. (2007). Patent fora-
61. Agrawal, S. K., Pinheiro, L., Roubin, G. S., et al. (1992). Nonsurgical clo- men ovale and the risk of ischemic stroke in a multiethnic population.
sure of femoral pseudoaneurysms complicating cardiac catheterization and Journal of the American College of Cardiology, 49(7), 797–802.
percutaneous transluminal coronary angioplasty. Journal of the American 82. Slottow, T. L., Steinberg, D. H., & Waksman, R. (2007). Overview of the
College of Cardiology, 20(3), 610–615. 2007 Food and Drug Administration Circulatory System Devices Panel
6
6
62. Frazee, B. W., & Flaherty, J. P. (1991). Septic endarteritis of the femoral meeting on patent foramen ovale closure devices. Circulation, 116(6),
artery following angioplasty. Reviews Infectious Diseases, 13(4), 620–623. 677–682.
63. Laskey, W. K., Yancy, C. W., & Maisel, W. H. (2007). Thrombosis in coro- 83. Sacco, R. L., Adams, R., Albers, G., et al. (2006). Guidelines for preven-
nary drug-eluting stents: Report from the meeting of the Circulatory Sys- tion of stroke in patients with ischemic stroke or transient ischemic attack:
tem Medical Devices Advisory Panel of the Food and Drug Administra- A statement for healthcare professionals from the American Heart Associ-
tion Center for Devices and Radiologic Health, 7–8 December 2006. ation/American Stroke Association Council on Stroke: Co-sponsored by
Circulation, 115(17), 2352–2357. the Council on Cardiovascular Radiology and Intervention: The American